HK

Hyun Kim

Vice President, HealthQuest Capital

Houston, Texas

Invests in

Stages:

  • Min Investment:

    $15,000,000.00
  • Max Investment:

    $50,000,000.00
  • Target Investment:

    $25,000,000.00

Work Experience

  • Vice President

    2022

    Healthcare growth equity fund focused on medical products, devices, diagnostics, consumer health, healthcare services, and healthcare IT

  • Senior Associate

    2017 - 2022

    Special situations investing in commercial or near commercial biopharma companies or products; involved in 7 deals with cumulative deal value >$1B. Notable deals include Shingrix (GSK), Zolgensma (Novartis), and Krystexxa (Horizon Therapeutics).

2016 - 2017

  • Investment Banking Analyst

    2016 - 2017

    Biopharma investment banking, advising on M&A, licensing deals, and capital raises for emerging biotech companies. Notable deals include Intellia Therapeutics (NTLA), Beigene (BGNE), Vericel (VCEL), and Dermira (DERM).

2015 - 2015

  • Finance Accounting Intern

    2015 - 2015

    Part-time FP&A role within Invivo Corporation, a subsidiary of Philips Healthcare that focuses on manufacturing MRI coils

2015 - 2015

  • Sales Representative

    2015 - 2015

    Part-time door-to-door lab equipment sales at the University of Florida campus

2013 - 2014

  • Intern

    2013 - 2014

    Intern at HealthQuest

2014 - 2014

  • FMP Analyst Intern

    2014 - 2014

    Intern in the Healthcare Financial Services division, which focused on lending to healthcare real estate entities (e.g. SNFs, NFs, and ALFs)